Novamind Grants Restricted Share Units

Rhea-AI Summary

Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) announced on March 11, 2022, the grant of 325,000 restricted share units (RSUs) to executives and employees. The RSUs will vest in 25% intervals every six months. These units and underlying common shares will be subject to a four-month and one-day hold period under Canadian Securities Exchange policies. Novamind is focused on mental health treatment via psychedelic medicine, providing services such as ketamine-assisted psychotherapy and conducting clinical trials for innovative mental health solutions.

Positive

• Grant of 325,000 restricted share units to executives and employees, aligning their interests with shareholder value.
• RSUs vest in structured intervals, fostering long-term commitment and stability within the company.

Negative

• None.

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

TORONTO, ON / ACCESSWIRE / March 11, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, announces that it has granted an aggregate of 325,000 restricted share units ("RSUs") effective March 11, 2022, to certain executives and employees of the Company pursuant to its restricted share unit plan. The RSUs will vest in 25% intervals, every 6 months from the date of the grant.

The RSUs and any underlying common shares in the capital of the Company will be subject to a four month and one day hold period pursuant to the policies of the Canadian Securities Exchange.

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of integrative mental health clinics and operates a full-service contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Investor Relations
Email: IR@novamind.ca

None of the securities to be issued pursuant to the Transaction have been or will be registered under the United States Securities Act of 1933, as amended, or any state securities laws, and any securities issued pursuant to the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will only update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

View source version on accesswire.com:
https://www.accesswire.com/692644/Novamind-Grants-Restricted-Share-Units

FAQ

What is the recent announcement by Novamind (NVMDF) regarding RSUs?

On March 11, 2022, Novamind announced the granting of 325,000 restricted share units to its executives and employees.

When will the restricted share units granted by Novamind (NVMDF) vest?

The restricted share units will vest in 25% intervals every six months from the grant date.

What is the hold period for the restricted share units from Novamind (NVMDF)?

The RSUs and any underlying shares will be subject to a four-month and one-day hold period.

What is the focus of Novamind (NVMDF) as a company?

Novamind specializes in mental health care through psychedelic medicine and operates clinics and research sites.